Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
PAST TOP PICK

Pfizer Inc(PFE)

Mar 08, 2007
(A Top Pick Dec 21/06. Down 2.5%.) Sold their consumer business. There is so much value there. New management is cutting costs. 4.7% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.41

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 12, 2007
Pays a nice dividend. Have tons of cash through their normal cash generation as well as selling their consumers product division. Using some of it to increase dividends and some to buy back shares. 13 X earnings.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.22

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 01, 2007
This is a balance sheet story. They have a huge balance sheet that they can’t do anything with. Volatility in the stock price has fallen. New management wants to fire 10,000 people, etc. and it sounds like he wants to reduce the balance sheet. A restructuring story. 5% dividend. His current model price is $40, a 51% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.62

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 25, 2007
Drug companies have been struggling under generic competition as well as a difficult regulatory environment. Looks like compelling value here but would be more comfortable at $24.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$26.36

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2007
Hard one to play because it's in the drug space and there is a lot of litigation happening. From a trading perspective, this is a dangerous one to play.
Photo of John ManleyJohn Manley
No
Unlock Rating
$26.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 22, 2007
Big pharmaceutical pipelines product lines are getting squeezed and they have to cut costs. Relatively cheap, but the growth rate is not as good as it was.
Photo of John ZechnerJohn ZechnerUnlock Rating
$26.95

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 15, 2007
Like many of the pharmaceuticals, it is a company in transition. Won't go up aggressively, but it pays a decent yield. Historically, these companies have done well and they throw off a lot of free cash flow. New management is expected to cut costs and the company is buying back stock. Good balance sheet. Cheap.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.64

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 09, 2007
They have a great balance sheet and a yield over 4%. If you own, he would stick with it at this time.
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$26.17

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 04, 2007
Had a number of one time issues that have been happening which has made it a bad investment for the last 5 years. Probably near its bottom now. Would consider it in the $21 area.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$26.38

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 03, 2007
If you want to stay in the pharmaceutical space, he would prefer Eli Lilly (LLY-N).
Photo of Steve MacMillanSteve MacMillan
No
Unlock Rating
$26.29

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 21, 2006
His model price is $39. That’s a 49% positive differential. Looking out 1 year with their earnings, it’s a 15% return, plus the dividend of 4.4% gives a 20% implied rate of return.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 18, 2006
Pulled a replacement for Lipitor because of poor tests. Wasn’t going to contribute until 2010. Stock dropped. Near its all time low. Pristine balance sheet. Oversold.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$25.83

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 12, 2006
Likes the pharmaceutical industry, as it is undervalued. In the long term, it will come back. They will have to cut costs dramatically over the next several years. Cheap. Pays a 4% yield. Defensive. Won’t have dramatic moves.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.17

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 05, 2006
One for over 1, 2 and 3 years. Lost their major new blockbuster drug, but it wasn’t due on the market until Lipitor came off patent, 4 years out. Has $38 billion in cash and generates about $14 billion cash a year. Dividend yield of 3.9% and sees it going up a lot.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 05, 2006
What happened to their drug yesterday will probably mean the stock will stay down for awhile.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$24.82

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 586 to 600 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.86$313.26
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like